Comparability of Pharmacokinetics, Safety, and Tolerability of Canakinumab Administration With One Injection (200 mg) of Pre‐Filled Syringe or Auto‐Injector Versus Two Injections (150 and 50 mg) of Pre‐Filled Syringe in Healthy Subjects
Clinical Pharmacology in Drug Development · 2026-11 · 15 (11)
DOI: 10.1002/cpdd.70109 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 04.11.2026. Verfasst von Abhijit Chakraborty und 7 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Institutes for Biomedical Research, East Hanover, NJ, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Novartis.
Abstract (Originalsprache)
This phase 1, randomized, open‐label, single‐dose, parallel‐group study aimed to describe the pharmacokinetic (PK) comparability and safety of canakinumab administered as a single 200 mg subcutaneous injection via pre‐filled syringes assembled within a needle safety device (PFS‐NSD) by HCP and auto‐injector (AI) by subject self‐administration versus two injections of 150 + 50 mg via PFS‐NSD by HCP. Healthy adults (18–55 years) were allocated to three arms: canakinumab 150 + 50 mg (PFS‐NSD; n = 78), canakinumab 200 mg (AI; n = 76), and canakinumab 200 mg (PFS‐NSD; n = 76). Multiplicity was addressed as two tests were compared with the same reference. Primary PK parameters were comparable across arms. The geometric mean ratios and 95% CI values of AUC inf , AUC last , and C max were within bioequivalence limits of 0.80‐1.25 for both comparisons: (a) canakinumab 200 mg AI versus canakinumab 150 + 50 mg PFS‐NSD and (b) canakinumab 200 mg PFS‐NSD versus canakinumab 150 + 50 mg PFS‐NSD. Median T max was comparable: 7, 9, and 7 days for canakinumab 150 + 50 mg PFS‐NSD, 200 mg AI, and 200 mg PFS‐NSD, respectively. Exploratory post‐hoc analyses, assessing the impact of pause during the pandemic (N = 131 subjects recruited pre‐pandemic) and evaluating partial AUC 4weeks , suggested similar results. Canakinumab was well‐tolerated, and no treatment‐induced immunogenicity was observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novartis Institutes for Biomedical Research, East Hanover, NJ, USA.
- Insmed, NJ, USA.
- Novartis Pharma AG, Basel, Switzerland.
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Förderung
- Novartis
Zitieren
APA
Chakraborty, A., Marathe, A., Lee, J. B., Wiedinger, K., Zehnpfennig, B., Schuhler, C., Eddy, S., & Quinlan, M. (2026). Comparability of Pharmacokinetics, Safety, and Tolerability of Canakinumab Administration With One Injection (200 mg) of Pre‐Filled Syringe or Auto‐Injector Versus Two Injections (150 and 50 mg) of Pre‐Filled Syringe in Healthy Subjects. Clinical Pharmacology in Drug Development, 15(11). https://doi.org/10.1002/cpdd.70109
Vancouver
Chakraborty A, Marathe A, Lee JB, Wiedinger K, Zehnpfennig B, Schuhler C, et al. Comparability of Pharmacokinetics, Safety, and Tolerability of Canakinumab Administration With One Injection (200 mg) of Pre‐Filled Syringe or Auto‐Injector Versus Two Injections (150 and 50 mg) of Pre‐Filled Syringe in Healthy Subjects. Clinical Pharmacology in Drug Development. 2026;15(11). doi:10.1002/cpdd.70109
BibTeX
@article{Chakraborty2026,
author = {Chakraborty, Abhijit and Marathe, Anshu and Lee, Jong Bong and Wiedinger, Kari and Zehnpfennig, Britta and Schuhler, Carole and Eddy, Simantini and Quinlan, Michelle},
title = {Comparability of Pharmacokinetics, Safety, and Tolerability of Canakinumab Administration With One Injection (200 mg) of Pre‐Filled Syringe or Auto‐Injector Versus Two Injections (150 and 50 mg) of Pre‐Filled Syringe in Healthy Subjects},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cpdd.70109}
}
EUVIMED